Tectonic Therapeutic (NASDAQ:TECX) recently announced positive interim results from its phase 1b study using Fc-fusion protein TX45 for the treatment of patients with Group 2 pulmonary ...
Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...
Tectonic Therapeutic TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ...
Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer said that an early-stage trial for its lead candidate TX45 achieved its ...
The TX45 treatment demonstrated significant improvements in left ventricular function and pulmonary hemodynamics, supporting the ongoing APEX Phase 2 clinical trial.
Tectonic Therapeutic, Inc.'s stock surged 120% after positive Phase 1b data for TX45 in treating PH-HFpEF, a condition with no approved therapies. TX45, an Fc-relaxin fusion protein, showed ...
Investing.com -- Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...
Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.
TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin.